NAD+ — nicotinamide adenine dinucleotide — has become the highest-margin add-on at men's health clinics. The pitch is compelling: a coenzyme essential for cellular energy production, DNA repair, and sirtuin activation that declines with age. Replenish it, the story goes, and you'll recover faster, think clearer, age slower, and feel twenty years younger.
The biochemistry is real. The marketing claims built on it are several evidentiary steps ahead of where the published human data actually stands.
The Biochemistry (What's Actually True)
NAD+ is genuinely one of the most important molecules in cellular metabolism. It serves as an electron carrier in the mitochondrial electron transport chain — the process that generates ATP, the cell's energy currency. Without adequate NAD+, mitochondrial function deteriorates, energy production declines, and cellular repair mechanisms falter.
NAD+ also activates sirtuins — a family of proteins involved in DNA repair, inflammation regulation, and cellular stress responses. The sirtuin-NAD+ connection is the basis of much of the anti-aging interest: in model organisms (yeast, worms, mice), boosting NAD+ extends healthspan and sometimes lifespan.
And yes, NAD+ declines with age. Studies measuring NAD+ levels in human tissue show progressive decline starting around age 40, with tissue-specific variations. This decline correlates with age-related metabolic dysfunction, though the causal direction isn't fully established — does declining NAD+ cause aging, or does aging cause NAD+ decline?
The Evidence Gap (Where Claims Outpace Data)
Preclinical vs. Clinical
Most of the compelling NAD+ data comes from animal models. Mice receiving NAD+ precursors (NMN, NR) show improved mitochondrial function, enhanced exercise capacity, better insulin sensitivity, and extended healthspan. These results are consistent and reproducible in rodents.
The human translation is where things thin out:
- NMN human trials: A small number of human trials (mostly under 100 participants) have shown that NMN supplementation increases blood NAD+ levels. Whether this translates to functional benefits is still being studied. A 2022 trial in Science showed NMN improved insulin sensitivity in prediabetic women — one of the first human functional outcomes.
- NR human trials: Similar story. Nicotinamide riboside (NR, sold as Niagen/TruNiagen) raises NAD+ in humans, but published functional benefits in healthy adults are minimal. The most cited trial showed increased NAD+ levels without measurable improvements in muscle mitochondrial function or exercise performance.
- IV/injection NAD+: Direct NAD+ infusion or injection bypasses the oral absorption question but has very few published human trials. Most evidence is anecdotal or from clinic-reported outcomes that haven't undergone peer review.
The Men's Optimization Context
For men already on TRT, GLP-1s, and other therapies, the question is whether adding NAD+ injections produces measurable improvement beyond what their existing stack already provides. This specific question — NAD+ as an add-on to an optimized men's health regimen — has essentially zero published human data. The clinic experience is "patients report feeling better," which is valuable but doesn't separate NAD+ effects from placebo, lifestyle changes, or the other therapies in the stack.
Delivery Methods Compared
| Method | NAD+ Level Increase | Cost | Evidence |
|---|---|---|---|
| Oral NMN (supplement) | Moderate | $40–$100/mo | Multiple small human trials |
| Oral NR (supplement) | Moderate | $40–$80/mo | Several human trials |
| Subcutaneous injection | High (direct) | $200–$400/mo | Very limited human data |
| IV infusion | Very high (direct) | $500–$1,000/session | Minimal published data |
The injection and IV routes deliver NAD+ directly, bypassing digestion and absorption. Clinics argue this produces meaningfully higher tissue levels. Researchers counter that NAD+ injected systemically may not efficiently enter cells — the molecule is large and doesn't cross cell membranes passively. Much of injected NAD+ may be metabolized extracellularly before reaching its intracellular targets.
What an Informed Decision Looks Like
NAD+ Decision Framework
- The biochemistry is solid: NAD+ genuinely matters for cellular health, and it genuinely declines with age.
- The supplementation evidence is early: NMN and NR raise NAD+ levels in humans. Functional benefits are starting to emerge in small trials but aren't established.
- The injection evidence is very early: Direct NAD+ injection has minimal published human outcomes data.
- The cost is significant: $200–$400/month for injections, or $500–$1,000 per IV session. That's real money for uncertain benefit.
- The honest position: You're paying for biochemical plausibility and preclinical promise. That may be worthwhile to you — but it's different from paying for proven clinical benefit.
The Bottom Line
Promising Biology, Premature Conclusions
NAD+ is a genuinely important molecule, and its age-related decline is real. The leap from that biology to "injectable NAD+ will make you feel twenty years younger" is larger than most clinic marketing acknowledges. If you choose to add NAD+ to your regimen, do it with open eyes about what the evidence does and doesn't support, and don't let it divert budget from therapies with established human outcomes data — like properly dosed TRT, effective GLP-1 treatment, and evidence-based cardiovascular management.